Andres R Y, Schubiger P A, Tiefenauer L, Seybold K, Locher J T, Mach J P, Buchegger F
Swiss Federal Institute for Reactor Research, Würenlingen.
Eur J Nucl Med. 1988;13(11):582-6. doi: 10.1007/BF02574773.
Current nuclear medicine techniques for the localization of inflammatory processes are based on injection of 111In labelled autologous granulocytes which need to be isolated and radiolabelled in vitro before reinjection. A new technique is presented here that obviates the need for cell isolation by the direct intravenous injection of a granulocyte specific 123I labelled monoclonal antibody. In this publication the basic parameters of the antibody granulocyte interaction are described. Antibody binding does not inhibit vital functions of the granulocytes, such as chemotaxis and superoxide generation. Scatchard analysis of binding data reveals an apparent affinity of the antibody for granulocytes of 6.8 X 10(9) l/mol and approximately 7.1 X 10(4) binding sites per cell. Due to the high specificity of the antibody, the only expected interference is from CEA producing tumors.
当前用于炎症过程定位的核医学技术是基于注射111铟标记的自体粒细胞,这些粒细胞在重新注射前需要在体外进行分离和放射性标记。本文介绍了一种新技术,该技术通过直接静脉注射粒细胞特异性123碘标记的单克隆抗体,避免了细胞分离的需要。在本出版物中描述了抗体与粒细胞相互作用的基本参数。抗体结合并不抑制粒细胞的重要功能,如趋化性和超氧化物生成。对结合数据的Scatchard分析显示,抗体对粒细胞的表观亲和力为6.8×10⁹ l/mol,每个细胞约有7.1×10⁴个结合位点。由于抗体的高特异性,唯一预期的干扰来自产生癌胚抗原(CEA)的肿瘤。